MLICM
ATNM icon

Metropolitan Life Insurance Company (MetLife)’s Actinium Pharmaceuticals ATNM Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,434
Closed -$11.2K – 201
2024
Q1 		$11.2K Hold
1,434
– – ﹤0.01% 2092
2023
Q4 		$7.29K Hold
1,434
– – ﹤0.01% 2256
2023
Q3 		$8.49K Hold
1,434
– – ﹤0.01% 2281
2023
Q2 		$10.6K Buy
+1,434
New +$12.2K ﹤0.01% 2269

Other funds holding ATNM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ATNM Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Actinium Pharmaceuticals (ATNM) in Q2 2024, closing a stake of 1,434 shares — an estimated $11.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ATNM in Q2 2023 and held it in 4 quarters. The position peaked at $11.2K in Q1 2024. 74 funds tracked by Wall St. Rank hold ATNM as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Actinium Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,434 Actinium Pharmaceuticals shares in Q2 2024, an estimated $11.2K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Actinium Pharmaceuticals in Q2 2023 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Actinium Pharmaceuticals position peaked at $11.2K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.